Introduction
Germline mutations in the von Hippel ± Lindau tumor suppressor gene (VHL) and somatic inactivation of the other allele result in highly vascularized tumors such as clear cell renal carcinoma, retinal angioma and hemangioblastomas of the central nervous system (for reviews, see Gnarra et al., 1996; Kaelin and Mahler, 1998) .
The human VHL (h-VHL) gene encodes two polypeptides of 213 and 160 amino acids, resulting from in-frame alternative start codon usage (Latif et al., 1993; Iliopoulos et al., 1998) . Although there is no extensive homology between VHL and other known proteins, recent studies have shown that VHL, together with elongin B/C, cullin-2 and Rbx1, forms an E3 ubiquitin ligase complex (Iwai et al., 1999; Lisztwan et al., 1999; Pause et al., 1999) . Thus, VHL may be involved in recognizing speci®c protein targets and mediate their degradation through ubiquitination.
The best characterized VHL function thus far has been its involvement in hypoxia-induced angiogenesis. Supporting this functional role is the identi®cation of one of its degradation targets: the a subunit of the hypoxia-inducible factor 1 (Hif-1a; Wang et al., 1995; Maxwell et al., 1999) . Hif-1 is a transcription activator that mediates the hypoxia-induced up-regulation of vascular endothelial growth factor (VEGF) expression (Maxwell et al., 1997) , which is a potent inducer of angiogenesis (Leung et al., 1989; Shweiki et al., 1992) . VHL can therefore be considered an anti-angiogenic factor and this function can explain the over-vascularized phenotypes in the VHL tumors.
However, this view was inconsistent with the ®nding that germline VHL knockout mice showed embryonic lethality due to a lack of vascularization in the placenta (Gnarra et al., 1997) . In an attempt to resolve this apparent contradiction, we sought to study the VHL function in an experimentally accessible in vivo system, Drosophila melanogaster. We showed that the Drosophila VHL (d-VHL) is highly conserved as compared to the human counterpart and has a role in the development of the Drosophila vasculature, the tracheal system. Reduction of d-VHL activity can either disrupt or induce vascular growth, depending on the nature of the tracheal branches. A model for the d-VHL function is proposed that underlies the seemingly contradictory phenotypic outcomes.
Results

Cloning of the d-VHL gene sequence
A segment of the human h-VHL open reading frame (ORF) corresponding to amino acid residues 59 ± 208 was used as a query to search the Berkeley Drosophila Genome Project database (http://www.fruit¯y.org). An uninterrupted VHL-like ORF was identi®ed within two P1 contigs DS00724 and DS00284 (GenBank accession #AC006066) encompassing the chromosomal 2R region 47D6 ± 47E6. In order to determine whether or not the identi®ed sequence is transcribed in vivo, reverse transcription-coupled polymerase chain reaction (RT ± PCR) was performed on either ovarian or embryonic RNA samples. Both produced cDNA fragments of expected size of about 600 base-pairs.
They were con®rmed by sequence analysis to be identical to the genomic sequence. Therefore there are no small introns embedded in the ORF.
The candidate 178-amino acid d-VHL protein can be aligned along its entire length with the smaller of the two h-VHLs ( Figure 1a ; Gnarra et al., 1994; Beroud et al., 1998; Stebbins et al., 1999) . d-VHL has an overall 22% identity to h-VHL and is 50% similar when conserved amino acid changes were considered ( Figure  1b ). In the two functionally signi®cant protein interaction domains, human residues 113 ± 121 and 157 ± 172 that encompass the protein kinase Cl (PKCl) and the elongin C binding sites, respectively (Okuda et al., 1999; Kibel et al., 1995) , the conservation is signi®cantly higher at 67 and 76%.
The hallmark of h-VHL activity is its ability to bind elongin C. Since the Drosophila elongin C (d-elongin C) has been cloned and it showed over 90% identity to the human counterpart (Aso and Conrad, 1997), we tested whether or not the putative d-VHL can bind to d-elongin C. As shown in Figure 2a , the puri®ed d-VHL can interact with d-elongin C without the presence of other factors such as elongin B. The binding activity of d-VHL appears to be selective since the majority of the protein present in the binding reaction were not bound by d-VHL (Figure 2a , lower panel). It is worth noting that in a similar experiment, d-VHL did not interact speci®cally with d-elongin B (data not shown). We henceforth consider the isolated VHL-like sequence a true homolog of the mammalian counterparts.
d-VHL was then mapped more precisely to a single polytene chromosomal position at 47E1-3 (Figure 2b) , consistent with the location of the P1 clones. Two transcripts of 1.4 and 1.2 kb were detected in developmental Northern analysis (Figure 2c ). The gene is expressed at low levels in embryo, pupa, and adults, and at a very low level in larva. One cDNA clone of 1.287 kb was subsequently isolated from an ovarian library (Stroumbakis et al., 1994) . Sequence analysis (submitted to GenBank, accession #AF195836) showed that there are no introns in the 141 bp 5' or the 669 bp 3' untranslated regions.
Expression pattern of d-VHL
Whole-mount RNA in situ hybridization was performed on the developing embryos in order to assess the function of d-VHL. In the ®rst 12 h of development at 258C (stages 1 ± 14), there is no speci®c tissue staining, although an above-background general staining is observed (Figure 3a,b) . At stage 15, or *12 ± 13 h after egg laying, speci®c staining appears in the main dorsal trunk of the tracheal system ( Figure 3c ) and gradually progresses into other, smaller branches at later stages (Figure 3d ,e). This temporal pattern appears to lag behind the progression of branching outgrowth in the trachea. This is best illustrated when the d-VHL expression pattern is compared to that of the Trachealess (Trh) protein, a transcription factor with structural similarity to the mammalian Hif-1a (Wilk et al., 1996) . Trh is expressed in all tracheal cells throughout tracheal development, starting from the formation of 10 trachea-forming subunits, termed tracheal placodes, on each side of the germband at stage 11. Cells within each tracheal placode invaginate from the epithelium and start branching and outgrowth at stage 12 (Figure 3f ). The largest tracheal tubes, the dorsal trunks (DT), are formed by horizontal fusion of the elongating tracheal subunits (Figure 3f,g ). The fusion of DT is nearly complete at stage 14 (Figure 3g ) while other cells continue to migrate perpendicularly to DT to form smaller branches. About 1 ± 2 h later, at stage 15, the DT formation is complete (Figure 3h ) and other branches continue to extend through stage 16 and 17 until the embryos mature (Figure 3i ,j). During this process, d-VHL expression appears only in the tracheal regions where cell migration and tube outgrowth no longer occur. This suggests that d-VHL may be involved in halting cell movement within the tracheal system. In light of this model, it is interesting to point out that d-VHL is expressed at a very low level at the larval stage (Figure 2b ), when extensive tracheal tube outgrowth is needed to keep pace with the rapid growth of body masses.
A role of d-VHL in regulating tracheal cell proliferation is not favored since the number of tracheal cells remains constant throughout tracheal development while d-VHL expression only appears at stage 15. Tube formation results solely from cell migration and elongation.
d-VHL loss-of-function phenotypes
Since there are no genomic mutations of d-VHL, we sought to study the in vivo function by using RNA interference (RNAi) methodology, a gene silencing (Heniko and Heniko, 1992) of the VHL proteins from human (h-VHL) and Drosophila (d-VHL). Identical residues are marked by vertical lines and similar residues are marked by (:) or (.), according to the degree of similarity. The alternative initiation codon for h-VHL is highlighted. Boxed residues are those identi®ed as minimally required for speci®c protein interaction as indicated. (b) Extent of homology between Drosophila and human VHL proteins strategy mediated by double-stranded (ds) RNA (Fire et al., 1998; Kennerdell and Carthew, 1998) . ds RNA encompassing the coding region of d-VHL was produced in vitro and injected into embryos. ds lacZ RNA was used as a negative control. The eects of RNAi on reducing the level of the endogenous d-VHL RNA was monitored by RNA in situ hybridization (compare Figure In one example (Figure 4c ), an ectopic transverse connective (TC) grew out of an over-extended visceral branch (VB), while branches of the lateral trunks (LT) showed abnormal looping. Interestingly, the ectopic branching and looping observed here resemble the hypoxia response demonstrated in Drosophila (Jarecki et al., 1999; Wingrove and O'Farrell, 1999) .
The largest tubes in the tracheal system, the dorsal trunks (DT), appeared to respond dierently from the other tubes to d-VHL loss-of-function. As suggested by the RNA expression pattern, d-VHL may be involved in halting tracheal cell movement after tube outgrowth is complete. This may be particularly important for the dorsal trunk, which requires precise lateral outgrowth and interconnection from 10 axially laid out subunits (Figure 3f ± h). When d-VHL activity is inhibited, DT cells may continue moving and/or migrate ectopically without fusing with the opposing tubes. On the contrary, the smaller branches grow out from existing tubes and have free migrating ends. Uncontrolled cell migration in these branches can therefore result in excessive and ectopic looping and branching.
In support of this model, we also observed ectopic migration of Trh-expressing cells in d-VHL dsRNAinjected embryos, at the expense of DT formation ( Figure 3k ).
d-VHL gain-of-function phenotypes
If the proposed function of d-VHL is correct, one prediction would be that, in a gain-of-function d-VHL mutant, DT formation will also fail since cell migration is inhibited. The dierence from the loss-of-function mutant would be a reduced capability of the small branches to produce additional outgrowth. In other words, there will be a general lack of vascularization.
The gain-of-function mutant was generated by injecting the embryos with capped sense d-VHL RNA. It was immediately obvious that the RNAi phenotype described above occurred only at the background level (Table 1) . The other seemingly varied phenotypes appeared to be dierent extents of the same theme, i.e., repressed tracheal development. Two examples are shown: no tracheae at all (Figure 4f ) and broken dorsal trunk without smaller branches (Figure 4g ). The overexpression was monitored by RNA in situ hybridization, which showed excessive sense RNA accumulation at stage prior to normal tracheal expression of the endogenous d-VHL (compare Figures 4f ' with 3b' ). Capped sense lacZ RNA was used as a negative control and it showed no speci®c eects (Table 1) .
In order to determine whether or not h-VHL is functionally equivalent to d-VHL, the h-VHL sense RNA was injected into the embryos. Signi®cantly, h-VHL could induce the similar gain-of-function phenotype ( Figure 4h and Table 1 ). Over-expression of h-VHL was monitored by RNA in situ hybridization (Figure 4h') . It is worth noting that h-VHL has recently been shown to inhibit branching morphogenesis of the renal carcinoma cells (Koochekpour et al., 1999) . Lack of cell movement in these mutants could also be In this study, we showed the identi®cation of the Drosophila homolog of the human VHL tumor suppressor gene. This is supported by the high degree of structural similarity (50% overall) between the two presumptive protein sequences. Signi®cantly, the amino acid conservation is spread throughout the entire length of d-VHL (Figure 1a ). In the functionally signi®cant domains of PKCl and elongin C binding domains, the similarity is much higher at 67 and 76%, respectively (Figure 1b) . Indeed, the Drosophila VHL homolog can interact with the Drosophila elongin C, an essential function ascribed to the VHL protein ( Figure  2a) . One outstanding distinction between the two proteins, however, is that d-VHL lacks the N-terminal extension found in the larger form of the h-VHL. h-VHL gene encodes two biologically active proteins as a result of in-frame alternative AUG codon usage (Gnarra et al., 1994; Beroud et al., 1998; Stebbins et al., 1999) . However, no functional signi®cance has been assigned to the extra 53 amino acids at the N-terminus of the large h-VHL. Underlying this fact are the following observations: First, the short h-VHL is sucient for the tumor suppressor function (Schoenfeld et al., 1998; Blankenship et al., 1999) . Second, no clinically relevant mutations have been mapped in the N-terminus (Beroud et al., 1998) . Third, the human Nterminal extension is not found in either of the two rodent (mouse and rat) VHLs. Finally, while the second initiation codon for h-VHL is¯anked by a highly conserved Kozak initiation signal, the ®rst initiation codon lacks such motif (Schoenfeld et al., 1998) .
The structural similarity between the human and thē y VHLs has been borne out by functional substitution of d-VHL by the human counterpart in the gain-offunction phenotypic study (Figure 4 ; also see below).
Genomic structure of d-VHL
d-VHL was mapped to the chromosomal position 47E1-3 (Figure 2b) , consistent with the genomic source of the P1 contigs where d-VHL was originally identi®ed. This region contains a handful of tRNA genes and one recently isolated lethal mutation that also aects border follicle cell migration in the egg chamber (Liu and Montell, 1999) . The identity of this potentially interesting gene is not known yet.
The isolation of a nearly full-length cDNA clone of d-VHL allowed for an analysis of the gene structure. The 1287 bp cDNA should correspond very closely to the 1.4 kb transcript detected in the Northern blot (Figure 2c ) considering that a poly(A) + tail is added in vivo. Unlike h-VHL, d-VHL has no introns in the ORF or in the 5' and 3' UTRs. The signi®cance of this dierence is not clear.
Developmental Northern (Figure 2c) showed that d-VHL is expressed in all developmental stage with the exception of lava, which requires extensive tracheal outgrowth. Although we show here that d-VHL has a major function in tracheal development, we do suspect that d-VHL may have other developmental functions. For example, RNAi experiments showed that d-VHL de®ciency resulted in a higher level of early embryonic lethality (Table 1 ). The question of whether or not d-VHL is involved in modulating cell migration and tubulogenesis in general remains to be answered. It is interesting to note, however, that a weak expression of d-VHL RNA was detected in the embryonic salivary glands (unpublished observations), which contain an extensive duct system and requires also the function of the Trh (Isaac and Andrew, 1996) .
d-VHL function in tracheal development
Studies of d-VHL gene function presented here indicate that d-VHL is a component in the tracheal development pathway. This observation is of great signi®cance since Drosophila trachea is considered an excellent model for the mammalian vasculature. The branching morphogenesis in Drosophila and mammals is regulated by growth factors, such as the Drosophila Branchless ®broblast growth factor (FGF: Sutherland et al., 1996) and the mammalian FGF and VEGF (reviewed in Folkman and Shing, 1992; Risau, 1997) , by cell adhesion molecules such as cadherins (Tanaka-Matakatsu et al., 1996; Carmeliet et al., 1999) and by transcription factors such as the Hif-1-like factors Quantitation was based on the experiments described in Figure 4 .
b Large numbers of embryos did not survive the injection. These are designated`undeveloped' and could be identi®ed by their failure to develop any cuticular and internal structures.
c`P remature death' denotes those that failed to develop to term. Included in this category are those exhibiting obvious early patterning defects in axis determination and mesodermal dierentiation. About 28% of lacZ-injected embryos are of this category. This represents a background level of developmental defects induced by injecting foreign substances. A higher level of premature death is observed in d-VHL ds RNA samples, indicating an additional role of d-VHL in early embryonic development. These are not counted as direct tracheal detects. Only those developed past stage 15, judged by morphological landmarks such as discernible midgut and posterior spiracles (see Figure 4) were scored for tracheal phenotypes (Wilk et al., 1996; Crews, 1998; Wang et al., 1995) and Ets family of proteins Pardanaud and Dieterlen-LieÂ vre, 1993) . Importantly, terminal outgrowth in both systems can be in¯uenced by physiological conditions such as hypoxia (Shweiki et al., 1992; Jarecki et al., 1999; Wingrove and O'Farrell, 1999) . This study further strengthens the notion that mammalian vascular and Drosophila tracheal systems share the same evolutionary origin, which employ the homologous molecular pathways, including the VHL gene functions. More detailed molecular and genetic epistatic analyses are now underway to elucidate the role of VHL in vasculogenesis.
Based on the expression patterns and the phenotype analyses of d-VHL mis-expression, we propose that VHL is likely involved in halting cell movement at the end of vascular tube outgrowth. This is supported by the following observations: First, d-VHL RNA expression appears only in the fully connected and/or extended tracheal tubes (Figure 3) . Second, reduced d-VHL function resulted in ectopic looping of tracheal tubes with free migrating ends while disrupting the formation of major tubes requiring precise cell migration and fusion (Figures 3 and 4) . Third, overexpression of d-VHL resulted in inhibition of cell migration and, consequently, stunted tracheal tube formation (Figures 3 and 4) . This model can explain the two dierent VHL loss-of-function outcomes observed in knockout mice and human tumors. As observed in Drosophila, reduction of vhl function by RNA interference possibly lead to uncontrolled cell movement and disrupt the primary vasculature that requires stereotypical cell migration and branching. This is likely the analogous situation observed in the germline knockout mice. On the other hand, once the primary vascular structure is laid out, a lack of VHL activity, and hence excessive cell migration and branching, can simply lead to over-vascularization, as observed in the secondary branches of the Drosophila tracheae and in human tumors.
What then are the in vivo targets of d-VHL? Mammalian VHLs are thought to directly or indirectly down-regulate VEGF expression. However, the VEGF level increased in VHL 7/7 mice (Gnarra et al., 1997) . Therefore, the true in vivo action of VHL in the vasculo/angiogenic pathway is still unclear. In Drosophila, the vasculogenic and hypoxia-responsive factor appears to be Branchless FGF . Could d-VHL modulate tracheal cell migration by repressing the expression of branchless? Since d-VHL is expressed in the tracheal tubes while branchless is expressed in the neighboring cells, the true d-VHL target may very well be the FGF receptor gene breathless, not the ligand itself. Elucidating this pathway may ultimately shed lights on the mammalian VHL function.
Materials and methods
RT ± PCR
The d-VHL upstream primer, 5'-CCATTGCAGATCGGCT-TAGC, is located at 32 to 13 nucleotides upstream of the initiation codon. The downstream primer, 5'-ACTAACAAC-TAGGAGTGTGC, is located at 22 to 3 nucleotides downstream of the stop codon. RT ± PCR reactions were carried out as described (Hsu et al., 1992) . Embryonic or ovarian total RNA samples from the y, w strain were used. The resulting fragments were blunt-end cloned into the SmaI site of the pBluescript-KS vector (Stratagene). The two RNA sources yielded identical sequences.
d-VHL protein purification
The Drosophila VHL open reading frame (ORF) was cloned into the pET15b vector (from Novagen) for generating histidine-tagged recombinant protein in bacteria. The His-d-VHL protein is insoluble in the bacteria extract and the pellet was dissolved in Ni-column buer (5 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9) in the presence of 6 M guanidine hydrochloride. The protein extract was loaded onto the Ni-agarose column (from Novagen) and puri®ed according to supplier's instructions except that the recombinant protein was renatured by sequential washing with column buer containing 3, 1.5, 0.75 and 0 M guanidine hydrochloride while bound to the resin. The bound protein was then used for subsequent binding assays. d-VHL protein production was induced by 1 mM of isopropyl-b-thiogalactopyranoside for 3 h at 378C. Protein extracts from a 30 ml culture was loaded onto 2.5 ml bed-volume of resin. Total protein yield was *25 mg or 100 ng per 10 ml of resin.
Elongin C binding assay
The d-VHL-bound resin was made 50% slurry in the binding buer (40 mM HEPES, pH 7.9, 0.1 M KCl, 1 mM dithiothreitol, 50 mM ZnSO 4 , 0.1 mM EDTA and 10% glycerol). The Drosophila elongin C (d-elongin) ORF was obtained by RT ± PCR using speci®c primers. The DNA fragment was cloned into the pBluescript vector (from Stratagene) and veri®ed by nucleotide sequencing. The protein was synthesized in vitro using coupled transcription/translation reactions (TNT Coupled Reticulocyte Lysate Systems from Promega).
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S-methionine was included in the synthesis reaction to label the protein product. 1 mg of the d-elongin-containing plasmid (*3.4 kb) was used in a 50 ml reaction according to protocols provided by the supplier. One tenth of the reaction mixture (5 ml) was used in each subsequent binding reaction. Binding assay was carried out by combining the elongin C-containing mixture and 100 ng of the resin-bound d-VHL protein (20 ml of the 50% slurry) in a 50 ml solution containing the binding buer (see above). The binding mix was incubated at room temperature for 1 h, the supernatant was saved and the resin was rinsed two times 10 min each with 100 ml of the binding buer. The contents in the supernatant and in the resin after rinsing were subjected to SDS-polyacrylamide gel electrophoresis (a 10 ± 15 ± 20% step gradient gel) and autoradiography. Equivalent amount of Ni-agarose resin was used as negative controls in the binding assay.
Polytene chromosome hybridization
The cloned RT ± PCR fragment described above was labeled with digoxigenin using reagents supplied by Roche Molecular Biochemicals. Polytene chromosome in situ hybridization was as described (Pardue, 1986) .
In situ detection of gene expression RNA in situ and immunostaining followed published protocols (Mantrova and Hsu, 1998) . Digoxigenin-labeled antisense RNA was synthesized in vitro from the d-VHL cDNA clone described above using the DIG RNA Labeling Kit from Roche Molecular Biochemicals. The rat anti-Trh polyclonal antibody was a gift from B-Z Shilo of Weizman Institute, Israel, and was used at 1 : 1000 dilution.
RNA interference
PCR primers encompassing the T7 and T3 RNA polymerase promoters were used to amplify the d-VHL or the lacZ sequences in the pBluescript vector. The resulting fragments were used for in vitro RNA synthesis using the Riboprobe Transcription System (Promega). The two single-stranded RNAs were mixed in TE buer (10 mM Tris-HCl, pH 7/ 1 mM Na-EDTA) at 0.1 mg/ml each. The RNA mixture was heat-denatured for 5 min at 808C and was allowed to cool down to room temperature over 1 h. In these conditions, the annealing was usually complete as judged by electrophoretic mobility shift. The ds RNA was then ethanol-precipitated and resuspended in injection buer (5 mM KCl/0.1 mM Na-PO 4 , pH 7.8) at a ®nal concentration of 0.2 mg/ml. About 5 ± 10 pl was injected into each embryo. Early embryos of the wild-type Oregon-R strain were collected within 2 h of egglaying. Injection followed the standard procedures (Spradling, 1986) . Embryos were immersed in halocarbon oil (Halocarbon Products) to prevent drying and permit free exchange of gases. Injected embryos were allowed to develop at 188C for 48 h (low growth temperature helped survival from mechanical trauma) and were directly observed under a light microsocpe.
Over-expression by sense RNA injection Sense RNA for over-expression experiments were`capped' to approximate the structure of mRNA in vivo. In vitro synthesis of capped RNA was essentially the same as described above with the addition of 0.3 mM m 7 G(5')ppp(5')G (Stratagene). For the human VHL assay, the ORF was cloned into vector pcDNA3 (Invitrogen) between T7 and Sp6 promoters. RNA synthesis was as described above.
